

LIST OF TABLES

Table No.	Title	Page No.
2.1	Classification of liposomes according to size	13
2.2	Therapeutic indications of Gemcitabine	15
3.1	Experimental conditions for Gemcitabine HCl by UV method	39
3.2	Absorbance of Gemcitabine HCl at 268nm in Water and Methanol	39
3.3	Absorbance of Gemcitabine HCl at 268nm in Water	40
4.1	Optimization of RPM, vacuum, time.	49
4.2	Optimization of Hydration Time	50
4.3	Optimization of Sonication	50
4.4	Optimization of drug:lipid, lipid: cholesterol ratio in conventional liposomes(CL)	51
4.5	Optimization of drug:lipid and lipid mixture ratio in stealth liposomes(SL)	51
4.6	Optimization of drug:lipid and lipid mixture ratio in folate targeted liposomes(FT)	51
4.7	Comparison between CL,SL and FT formulations	52
4.8	FTIR spectral data of GEM pure drug and CL liposomal formulation	60
4.9	<i>In vitro</i> release of GEM liposomes at pH 7.4	66
5.1	Stability data of liposomal dispersion	71
6.1	IC ₅₀ of Liposomal suspension with HeLa and A549 cell lines	79
6.2	Cell cycle data of HeLa cells at 4 hrs	83
6.3	Cell cycle data of A549 cells at 4 hrs	84
6.4	Cell cycle data of A549 cells at 8 hrs	84
7.1	Effect of quantity of SnCl ₂ on radiolabeling of gemcitabine HCl formulations	107
7.2	<i>In vitro</i> stability of labeled gemcitabine formulations	107
7.3	Effect of DTPA on radiolabeling of gemcitabine formulations	108
7.4	Radiolabelling summary of gemcitabine formulations	108
7.5	Biodistribution of ^{99m} Tc labeled PD, CL, SL and FT Liposomes in mice	109
7.6	Biodistribution of ^{99m} Tc labeled CL and FT Liposomes in tumor bearing mice	110
7.7	Pharmacokinetics of ^{99m} Tc-CL/SL/FT/PD of blood in Swiss mice	114